This risk is particularly seen in patients with IBD and arthropathy, and COVID-19 infection is associated with anti-TNF, systemic corticosteroids, and rituximab and other immunosuppressant exposure, while TNF-alpha inhibitors and systemic corticosteroids were associated with a significantly increased risk of hospitalisation. This evidence concerns the gene TNF and inflammatory bowel disease.